Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 8/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4526023 | 0.95 | NR1H4 (0.46) | NR1H4KCNH2PARP1KDM4EALDH1A1 | |
| SCHEMBL4525330 | 0.85 | PABPC1 (0.36) | NR1H4KDM4EALDH1A1HPGD | |
| SCHEMBL4525870 | 0.84 | NR1H4 (0.43) | NR1H4KCNH2CHRM3ALDH1A1HSD17B10 | |
| SCHEMBL1244153 | 0.82 | NR1H4 (0.59) | NR1H4KCNH2ALDH1A1 | |
| SCHEMBL4521015 | 0.82 | ALDH1A1 (0.43) | NR1H4PARP1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL1243051 | 0.82 | NR1H4 (0.63) | NR1H4KCNH2 | |
| SCHEMBL4525523 | 0.81 | NR1H4 (0.64) | NR1H4KCNH2 | |
| SCHEMBL4710139 | 0.81 | NR1H4 (0.58) | NR1H4KCNH2 | |
| SCHEMBL4527308 | 0.81 | NR1H4 (0.64) | NR1H4KCNH2 | |
| SCHEMBL4532574 | 0.80 | PARP1 (0.44) | NR1H4KCNH2PARP1CHRM3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | NR1H4, NR1I2, GPBAR1 | NR1H4 1/4885KCNH2 3726/4885PARP1 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.